Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency

Biotest

Status and phase: Completed; Phase 3

Conditions: Congenital Hypofibrinogenemia; Congenital Afibrinogenemia

Treatments: Biological: BT524 (fibrinogen concentrate from human plasma)

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02065882

2011-004154-25 (EudraCT Number)

Biotest 984

Details and patient eligibility

About

The purpose of the study is to investigate pharmacokinetics, efficacy and safety of BT524 in patients with congenital fibrinogen deficiency.

Full description

The present study is designed as a prospective, open-label, multicentre, phase I/III study investigating the 14 day single-dose pharmacokinetic properties, efficacy and safety of BT524 following intravenous administration in the treatment or prophylaxis of bleeding in patients with congenital afibrinogenemia or severe congenital hypofibrinogenemia.

Enrollment: 36 patients

Sex: All

Ages: Under 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Known congenital afibrinogenemia or severe congenital hypofibrinogenemia
• Plasma fibrinogen activity ≤ 0.5 g/l and antigen ≤ 0.5 g/l
• Male or female
• Age 0 to 75 years, with the first ten patients will be 18 years or
• Presumed to be compliant with the study procedures and to terminate the study as scheduled
• Willing and able to be hospitalized for 3 days for the pharmacokinetic assessment (if applicable)
• Willing and able to be hospitalized - if required - in case of interventions (e.g., surgical procedures, major bleeds)
• Written informed consent by the patient, his/her parents or by the patient's legal / authorized representative as applicable

Exclusion criteria

• Known congenital dysfibrinogenemia
• Known bleeding disorder other than congenital fibrinogen deficiency
• History of esophageal variceal bleeding
• Known presence or history of venous/arterial thrombosis or thromboembolic event in the preceding 6 months
• Known presence or history of fibrinogen inhibitory antibodies
• Known presence or history of hypersensitivity to human fibrinogen or human plasma proteins e.g., immunoglobulins, vaccines or hypersensitivity to any of the excipients
• Known positive serology for HIV-1 and HIV-2
• Clinically relevant biochemical or hematological findings (except due to underlying disease or emergency bleeding) outside the normal range (at the investigator's discretion)
• Clinically relevant pathological findings in physical examination including electrocardiogram (ECG)
• Treatment with any fibrinogen concentrate and/or fibrinogen-containing product within 2 weeks prior to infusion of BT524
• Concomitant medication interacting relevantly with the coagulation system (e.g., low molecular weight heparin, unfractioned heparin, factor Xa inhibitors, factor IIa inhibitors or PY12 inhibitors) within 2 weeks prior to infusion of BT524
• Recent vaccination (within 3 weeks prior to infusion)
• Body weight (BW) below 22 kg for patients ≥ 6 years; BW below the 5th percentile of the normal range for children < 6 years (refers to local standard)
• End stage disease
• Abuse of drugs
• Unable to understand and follow the study requirements
• Participation in another interventional clinical study within 30 days before entering the study or during the study
• Pregnant/ nursing woman, or woman of childbearing potential not using reliable/ effective contraceptive method(s) during the study and at least one month after the last administration of study drug (e.g., oral/ injectable/ implantable/ insertable/ topical hormonal contraceptives, intrauterine devices, female sterilization, partner's vasectomy or condoms)
• Any other condition that, to the investigator's judgment, could have an impact on patient's safety or the study results
• Elective surgery during the 14 day PK blood sampling period
• Acute infection
• Clinically relevant increase or decrease in body temperature
• Actively bleeding or anticipated bleeding (including female menorrhea) at the time point of or within 7 days prior to infusion of BT524
• Surgery within 7 days prior to infusion of BT524
• Immobilization within 7 days prior to infusion of BT524
• Intake of alcohol or significantly increased intake of caffeine containing products within 24 hours prior to infusion of BT524
• Blood donation or comparable blood loss within 60 days prior to infusion of BT524
• Excessive physical exercise (extreme sports activities, sauna) within 72 hours prior to infusion of BT524

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

36 participants in 1 patient group

BT524

Experimental group

Description:

Single intravenous infusion of a fixed dose of 70 mg BT524 per kilogram body weight (BW)

Treatment:

Biological: BT524 (fibrinogen concentrate from human plasma)